1-800-345-8979
Request an Appointment
Find a Center
Contact Us

Daniel D. Esmaili, M.D.

“As a retina specialist, I feel privileged that my patients trust me with the precious gift of sight. I approach each patient as if they were my family member and aim to combine the most cutting edge technology with compassion and respect to provide each patient with a course of treatment that is customized to their unique needs.”

About

Dr. Daniel D. Esmaili is a board-certified ophthalmologist specializing in the medical and surgical treatment of diseases of the retina and vitreous, with a special interest in treating age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.

Dr. Esmaili is an accomplished author, researcher, and presenter. He has been actively involved in numerous research studies and clinical research trials, he has authored peer-reviewed publications and book chapters and is an oft-sought speaker at local and national scientific meetings.

Dr. Esmaili has received numerous awards, including being named to Super Doctors of Southern California three consecutive years. He obtained his medical degree with highest distinction from the Keck School of Medicine of the University of Southern California and completed a prestigious two-year surgical vitreoretinal fellowship at the Massachusetts Eye and Ear Infirmary (MEEI) of Harvard Medical School where he was selected as Chief vitreoretinal fellow. He also served as part of the full-time academic faculty at MEEI/Harvard where he also served as Medical Director of the Massachusetts Eye and Ear Retina Consultants satellite practice.

Education and Training

  • College
    Bachelor of Science in Physiological Sciences, the University of California at Los Angeles, Los Angeles, California
    (1994-1998)
  • Medical School
    Doctor of Medicine (with the highest distinction) from Keck School of Medicine, the University of Southern California
    (1999-2003)
  • Internship
    Transitional Intern, Scripps Mercy Hospital in San Diego, California
    (2003-2004)
  • Residency
    Resident in Ophthalmology, Doheny Eye Institute, University of Southern California Keck School of Medicine, Los Angeles, California
    (2004-2007)
  • Fellowship
    Vitreoretinal Fellow, Massachusetts Eye and Ear Infirmary (MEEI) of Harvard Medical School in Boston, Massachusetts
    (2007-2008)
  • Chief Vitreoretinal Fellow, Massachusetts Eye and Ear Infirmary (MEEI) of Harvard Medical School in Boston, Massachusetts
    (2009-2009)

Professional Affiliations

  • Board Certified by the American Board of Ophthalmology
  • American Academy of Ophthalmology (member)
  • American Society of Retina Specialists (member)

Publications/ Presentations

  • Esmaili DD, Boyer DS. Recent advances in understanding and managing retinal vein occlusions. F1000Res. 2018 Apr 16;7:467.
  • Payne JF, Clark WL, Bruce BB, Wykoff CC, Brown DM, Menke BM, Iverson SM, Allen KF, Boyer DS; Treat & Extend Protocol in Patients with Diabetic Macular Edema Study Group. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2018 Aug;125(8):1304-1306.
  • Esmaili DD. Iatrogenic Occlusion of the Ophthalmic Artery after Sodium Tetradecyl Sulfate Injection in the Forehead. Retin Cases Brief Rep. 2017 Winter;11 Suppl 1:S28-S30.
  • Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW; Diabetic Retinopathy Clinical Research Network. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol. 2016 Feb;134(2):127-34. doi: 10.1001/jamaophthalmol.2015.4599. Erratum in: JAMA Ophthalmol. 2016 Apr;134(4):469.
  • Papakostas TD, Lim L, van Zyl T, Miller JB, Modjtahedi BS, Andreoli CM, Wu D, Young LH, Kim IK, Vavvas DG, Esmaili DD, Husain D, Eliott D, Kim LA. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye (Lond). 2016 Jan;30(1):79-84.
    6: Thanos A, Esmaili DD, Eliott D. Cotton-Wool Spots Associated With Mild Nonprogressive Visual Loss. JAMA Ophthalmol. 2015 Dec;133(12):1471-2.
  • Esmaili DD. CHORIORETINAL ATROPHY IN ALAGILLE SYNDROME. Retin Cases Brief Rep. 2015 Fall;9(4):330-2.
    8: Munk MR, Jampol LM, Cunha Souza E, de Andrade GC, Esmaili DD, Sarraf D, Fawzi AA. New associations of classic acute macular neuroretinopathy. Br J Ophthalmol. 2016 Mar;100(3):389-94.
  • Giani A, Luiselli C, Esmaili DD, Salvetti P, Cigada M, Miller JW, Staurenghi G. Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization. Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5579-86.
  • Chen L, Wang K, Esmaili DD, Xu G. Rhegmatogenous retinal detachment due to paravascular linear retinal breaks over patchy chorioretinal atrophy in pathologic myopia. Arch Ophthalmol. 2010 Dec;128(12):1551-4.
  • Giani A, Esmaili DD, Luiselli C, Cigada M, Salvetti P, Miller JW, Staurenghi G. Displayed reflectivity of choroidal neovascular membranes by optical coherence tomography correlates with presence of leakage by fluorescein angiography. Retina. 2011 May;31(5):942-8.
  • Giani A, Cigada M, Esmaili DD, Salvetti P, Luccarelli S, Marziani E, Luiselli C, Sabella P, Cereda M, Eandi C, Staurenghi G. Artifacts in automatic retinal segmentation using different optical coherence tomography instruments. Retina. 2010 Apr;30(4):607-16.
  • Esmaili DD, Mukai S, Jakobiec FA, Kim IK, Gragoudas ES. Ocular melanocytoma. Int Ophthalmol Clin. 2009 Winter;49(1):165-75.
  • de Bruin DM, Burnes DL, Loewenstein J, Chen Y, Chang S, Chen TC, Esmaili DD, de Boer JF. In vivo three-dimensional imaging of neovascular age-related macular degeneration using optical frequency domain imaging at 1050 nm. Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4545-52.
  • O’Hearn TM, Fawzi A, Esmaili D, Javaheri M, Rao NA, Lim JI. Presumed ocular tuberculosis presenting as a branch retinal vein occlusion in the absence of retinal vasculitis or uveitis. Br J Ophthalmol. 2007 Jul;91(7):981-2.

Awards and Achievements

  • Heed Ophthalmic Foundation Fellowship Award
  • Pan-American Ophthalmological Foundation Paul Kayser International Scholarship Award
  • Selected as chief vitreoretinal fellow during his surgical vitreoretinal fellowship at the Massachusetts Eye and Ear Infirmary (MEEI) of Harvard Medical School
  • Full time academic faculty at MEEI/Harvard
  • Served as Medical Director of the Massachusetts Eye and Ear Retina Consultants satellite practice.
  • Named to Super Doctors of Southern California (2015-2018)

Common Vision Challenges by Age

20 - 40
Are you tired of glasses & contacts?
Are you curious about LASIK vision correction?

Take Our Free LASIK Self-Evaluation
40 - 50
Has your up-close vision become blurry?
Do you need reading glasses to see menus, text messages, labels, etc.?
50+
Are you experiencing cloudy, yellowed vision?
Have you been diagnosed with cataracts?

Take Our Free Cataract Self-Evaluation